Kimberly Shipley
Family · Yakima, WANPI 1083128524
Payments from drug & device makers
Across 275 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$742
- Novo Nordisk$541
- Boehringer Ingelheim$464
- Bayer$368
- AstraZeneca$308
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,211100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $1,189 |
| Pfizer | 51 | $742 |
| Novo Nordisk | 36 | $541 |
| Boehringer Ingelheim | 18 | $464 |
| Bayer | 17 | $368 |
| AstraZeneca | 18 | $308 |
| GSK | 10 | $206 |
| Exact Sciences | 9 | $187 |
| Lilly USA, LLC | 9 | $172 |
| Abbott | 5 | $136 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $123 |
| Amgen | 5 | $100 |
| Sumitomo Pharma America, Inc. | 4 | $99 |
| Johnson & Johnson | 4 | $99 |
| Astellas Pharma US Inc | 2 | $53 |
| Viatris Specialty LLC | 2 | $51 |
| Inspire Medical Systems, Inc. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Lundbeck LLC | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Merck | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$5,211 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 18 | $27,097 |
| JanuviaSitagliptin Phosphate | 16 | $13,587 |
| ValtrexValacyclovir Hcl | 13 | $10,476 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,815 |
| Estradiol | 36 | $4,589 |
| NexiumEsomeprazole Magnesium | 13 | $3,597 |
| Omeprazole | 135 | $2,312 |
| Levothyroxine Sodium | 209 | $2,001 |
| Duloxetine Hcl | 35 | $1,752 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,723 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $1,670 |
| Rosuvastatin Calcium | 171 | $1,648 |
| Atorvastatin Calcium | 161 | $1,632 |
| Losartan Potassium | 124 | $1,505 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $1,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $464 | $27,09718 claims |
| MerckJanuvia | $14 | $13,58716 claims |
| GSKIncruse Ellipta | $206 | $4,81511 claims |
| AstraZenecaNexium | $308 | $3,59713 claims |
| AbbVieSynthroid | $1,189 | $1,06923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Yakima
- Sarah PerlmanYakima$12K
- Tesa LinstadYakima$8K
- Melanie AdamsYakima$7K
- Frances HullYakima$6K
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.